Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
Trial details
- Registry ID
- NCT07623668
- Drugs studied
- Methylprednisolone, Privosegtor
TrialRedline tracks 9 clinical trials sponsored by Oculis: 4 Phase 3, 2 Phase 2 / 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation ResearchNCT07623668 | Methylprednisolone, Privosegtor | Recruiting | 2027-12Estimated |
| A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)NCT06172257 | Dexamethasone ophthalmic suspension (OCS-01), Vehicle | Completed | 2026-04-02Actual |
| A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryNCT05147233 | OCS-01, Vehicle | Completed | 2023-06-22Actual |
| A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryNCT06128369 | OCS-01, Vehicle | Terminated | 2024-05-02Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Clinical Study Evaluating Licaminlimab for Dry Eye DiseaseNCT07548632 | Artificial Tear Run-in, Vehicle of licaminlimab, licaminlimab | Active not recruiting | 2026-12Estimated |
| A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)NCT05066997 | Dexamethasone ophthalmic suspension (OCS-01), Vehicle | Completed | 2026-04-10Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| OCS-05 in Patients With Optic NeuritisNCT04762017 | OCS-05 +SoC (corticosteroid) IV administration | Completed | 2024-09-16Actual |
| Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye DiseaseNCT05896670 | Artificial tears, licaminlimab, vehicle of OCS-02 | Completed | 2024-03-27Actual |
| OCS-01 in Treating Inflammation and Pain in Post-cataract PatientsNCT04130802 | OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL | Completed | 2020-01-31Actual |
Names as written in the registry records.
NCT07548632 · Oculis
Before: Recruiting. After: Active not recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Pain at Visit 4.. After: Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Ocular Pain at Visit 4..
Before: Estimated. After: Actual.
Before: Apr 2026. After: 10 Apr 2026.
Before: Active not recruiting. After: Completed.
Before: Estimated. After: Actual.
Before: Apr 2026. After: 2 Apr 2026.
Before: Active not recruiting. After: Completed.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Ocular Pain at Visit 4.. After: Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Pain at Visit 4..